Risteys · H8_VERTIGINOTH

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — H82* Cause of death: ICD-10 — H82* 2 out of 7 registries used, show all original rules.	19
4. Check minimum number of events None	19
5. Include endpoints None	19
6. Filter based on genotype QC (FinnGen only)	19

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	220	142	78
Only index persons	198	130	68
Unadjusted period prevalence (%)
Whole population	0.00	0.00	0.00
Only index persons	0.00	0.00	0.00
Median age at first event (years)
Whole population	-	67.82	71.98
Only index persons	68.72	67.82	70.44

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	19	13	6
Unadjusted period prevalence (%)	0.00	0.00	0.00
Median age at first event (years)	64.88	60.55	74.25

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

unit

cases

controls

-log₁₀(p)

N cases

N controls

(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum

0.00

1.08

0.0

1.2

—

1.4

—

(3016771) Amylase [Enzymatic activity/volume] in Serum or Plasma

2.20

0.96

5.4

2.6

u/l

57.3

52.2

—

(3041096) Erythrocytes [Presence] in Urine by Automated

2.03

0.75

3.5

3.0

—

(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma

0.51

0.64

4.6

6.1

mmol/l

1.2

—

(3033658) Prothrombin time (PT) actual/Normal

1.90

0.63

2.2

4.9

91.2

85.5

—

(40771025) 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma

1.73

0.50

3.2

2.1

nmol/l

87.2

76.4

—

(3018010) Neutrophils/100 leukocytes in Blood

0.56

0.48

1.5

4.6

66.8

56.6

—

(3013826) Glucose [Moles/volume] in Serum or Plasma

1.71

0.47

5.3

5.2

mmol/l

6.9

6.7

0.20

(3023368) Bacteria identified in Blood by Culture

1.57

0.40

2.2

4.8

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

1.53

0.35

3.5

3.3

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

1.43

0.34

2.4

2.9

—

(3044889) 12 lead EKG panel

112

1.51

0.33

5.8

3.9

—

(3026910) Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma

1.46

0.32

4.7

2.7

u/l

29.5

68.8

1.53

(3004588) Protein electrophoresis panel - Serum or Plasma

0.00

0.22

0.0

4.9

—

(4094501)

0.00

0.22

0.0

1.0

—

(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection

0.00

0.22

0.0

1.1

—

(3020779) Urea [Moles/volume] in Serum or Plasma

0.00

0.22

0.0

4.0

—

11.6

—

(4010399)

0.00

0.22

0.0

1.6

—

(3005322) IgE [Units/volume] in Serum or Plasma

0.00

0.22

0.0

1.5

—

131.3

—

(3002109) Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma

0.00

0.22

0.0

1.5

—

(36660697) Celiac disease serology panel - Serum

0.00

0.21

0.0

1.0

—

(40768804) Tissue Pathology biopsy report

1.38

0.20

3.1

2.3

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

0.74

0.20

4.3

3.1

ng/l

16.5

27.5

—

(3002030) Lymphocytes/100 leukocytes in Blood

0.71

0.20

1.4

4.9

18.5

28.3

—

(3019069) Monocytes/100 leukocytes in Blood

0.74

0.20

1.4

5.0

9.0

8.6

—

(3006504) Eosinophils/100 leukocytes in Blood

0.74

0.20

1.4

4.7

2.3

2.4

—

(3006140) Bilirubin.total [Moles/volume] in Serum or Plasma

1.40

0.20

6.5

7.2

umol/l

13.3

12.3

0.16

(3026008) Bacteria identified in Urine by Culture

1.16

0.10

2.0

2.6

—

(1761868) Lipid panel - Serum or Plasma

0.74

0.10

3.4

3.0

—

(3015736) pH of Urine

0.79

0.10

2.6

3.3

—

(3022096) Basophils/100 leukocytes in Blood

0.79

0.09

1.4

4.7

0.5

0.6

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

0.85

0.09

3.9

2.8

—

(40768443) Skin Pathology biopsy report

0.00

0.0

1.4

—

(40769539) Bacteria identified based on 16S rRNA gene [Identifier] in Specimen by Sequencing

0.00

0.0

1.1

—

(46237023) Hepatitis B virus core and surface Ab and surface Ag panel - Serum

0.00

0.0

1.0

—

(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection

0.00

0.0

1.0

—

(3000330) Specific gravity of Urine by Test strip

0.00

0.0

2.6

—

(3052851) Hemolysis interference index of Serum or Plasma

0.00

0.0

2.1

—

(1761482) Bacteria [#/volume] in Urine by Culture

0.00

0.0

3.9

—

(36304419) Bacteria [Presence] in Urine

0.95

0.00

2.4

2.7

—

(3007778) Kappa light chains/Lambda light chains [Mass Ratio] in Serum

0.00

0.0

8.7

—

(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells

0.00

0.0

1.2

—

(3028271) Lactate [Moles/volume] in Capillary blood

0.00

0.0

4.0

—

2.0

—

(3046870) Tissue transglutaminase IgG Ab [Units/volume] in Serum

0.00

0.0

1.0

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

0.00

0.0

1.2

—

(3043362) Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay

0.00

0.0

1.0

—

(3001122) Ferritin [Mass/volume] in Serum or Plasma

0.88

0.00

1.9

2.4

ug/l

102.4

110.1

—

(3004490) Bicarbonate [Moles/volume] standard in Capillary blood

0.00

0.0

2.2

—

24.7

—

(3024891) Influenza virus A+B Ag [Presence] in Specimen

0.00

0.0

1.0

—

(3043723) Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.0

5.9

—

(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.8

—

(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection

0.00

0.0

1.8

—

(3002482) Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.8

—

(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.9

—

(3027450) Sjogrens syndrome-B extractable nuclear Ab [Units/volume] in Serum

0.00

0.0

1.2

—

(3044254) Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

3.4

—

(42529201) Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.0

7.8

—

263.4

—

(3044640) Blood type and Crossmatch panel - Blood

0.95

0.00

1.8

2.2

—

(3028531) Enolase.neuron specific [Mass/volume] in Serum or Plasma

0.00

0.0

1.0

—

16.0

—

(3012477) Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

2.0

—

(43534045) MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal

0.00

0.0

1.0

—

(3044491) Cholesterol non HDL [Mass/volume] in Serum or Plasma

0.00

0.0

1.3

—

(3031478) Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.6

—

(3011371) Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.1

—

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

0.00

0.0

2.8

—

147.6

—

(40758310) Human epididymis protein 4 [Moles/volume] in Serum or Plasma

0.00

0.0

1.0

—

90.1

—

(3003284) Neutrophil cytoplasmic Ab.perinuclear [Titer] in Serum by Immunofluorescence

0.00

0.0

1.5

—

(42870588) Differential panel, method unspecified - Blood

0.88

0.00

2.0

4.8

—

(3046524) Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay

0.00

0.0

1.0

—

(3021387) Prolactin [Units/volume] in Serum or Plasma

0.00

0.0

1.2

—

249.0

—

(3049717) Cytology report of Urine Cyto stain

0.00

0.0

1.8

—

(3003694) ABO and Rh group [Type] in Blood

1.03

0.00

1.2

1.4

—

(36305247) Microscopic observation [Identifier] in Isolate by Gram stain

0.00

0.0

1.4

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

0.94

0.00

3.3

3.7

—

(3030692) Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection

0.00

0.0

2.0

—

(3005895) Myoglobin [Mass/volume] in Serum or Plasma

0.00

0.0

1.8

—

597.8

—

(46235759) Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection

0.00

0.0

3.2

—

(40768793) Breast Pathology biopsy report

0.00

0.0

1.8

—

Mortality – FinRegistry

↥

Association

Association between endpoint H8_VERTIGINOTH and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have H8_VERTIGINOTH.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: H8_VERTIGINOTH – Vertiginous syndromes in diseases classified elsewhere

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

Extremity

rg [CI]

Extremity

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

NAME	H8_VERTIGINOTH
CONTROL_EXCLUDE	H8_INNER
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	H82
HD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	H82
COD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Vertiginous syndromes in diseases classified elsewhere

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints